Log In
BCIQ
Print this Print this
 

PRT2761

  Manage Alerts
Collapse Summary General Information
Company Portola Pharmaceuticals Inc.
DescriptionOral spleen tyrosine kinase (SYK) inhibitor
Molecular Target Spleen tyrosine kinase (SYK)
Mechanism of ActionKinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Ophthalmic (unspecified)
Indication DetailsTreat ophthalmic indications
Regulatory Designation
PartnerOra Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/05/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today